383 related articles for article (PubMed ID: 26778738)
1. Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.
Escudero-Vilaplana V; Garcia-Gonzalez X; Osorio-Prendes S; Romero-Jimenez RM; Sanjurjo-Saez M
J Clin Pharm Ther; 2016 Feb; 41(1):59-63. PubMed ID: 26778738
[TBL] [Abstract][Full Text] [Related]
2. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
3. CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload.
Bruch HR; Dencausse Y; Heßling J; Michl G; Schlag R; Skorupa A; Schneider-Schranz C; Wolf S; Schulte C; Tesch H
Oncol Res Treat; 2016; 39(7-8):424-31. PubMed ID: 27486873
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
5. Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies.
Fragomeno C; Roccabruna E; D'Ascola DG
Blood Cells Mol Dis; 2015 Dec; 55(4):382-6. PubMed ID: 26460263
[TBL] [Abstract][Full Text] [Related]
6. Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients.
Del Corso L; Biale L; Parodi EL; Russo R; Filiberti R; Arboscello E
Int J Clin Oncol; 2017 Apr; 22(2):380-386. PubMed ID: 27771776
[TBL] [Abstract][Full Text] [Related]
7. Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
Gattermann N; Jarisch A; Schlag R; Blumenstengel K; Goebeler M; Groschek M; Losem C; Procaccianti M; Junkes A; Leismann O; Germing U
Eur J Haematol; 2012 Mar; 88(3):260-8. PubMed ID: 22023452
[TBL] [Abstract][Full Text] [Related]
8. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
Goldberg SL
Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
[TBL] [Abstract][Full Text] [Related]
9. Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?
Karimi M; Azarkeivan A; Zareifar S; Cohan N; Bordbar MR; Haghpanah S
Hematology; 2012 Nov; 17(6):367-71. PubMed ID: 23168076
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
Kim IH; Moon JH; Lim SN; Sohn SK; Kim HG; Lee GW; Kim YS; Lee HS; Kwon KY; Kim SH; Park KT; Chung JS; Lee WS; Lee SM; Hyun MS; Kim H; Ryoo HM; Bae SH; Joo YD
Transfusion; 2015 Jul; 55(7):1613-20. PubMed ID: 25764017
[TBL] [Abstract][Full Text] [Related]
11. Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
Metzgeroth G; Dinter D; Schultheis B; Dorn-Beineke A; Lutz K; Leismann O; Hehlmann R; Hastka J
Ann Hematol; 2009 Apr; 88(4):301-10. PubMed ID: 18758781
[TBL] [Abstract][Full Text] [Related]
12. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
Jabbour E; Garcia-Manero G; Taher A; Kantarjian HM
Oncologist; 2009 May; 14(5):489-96. PubMed ID: 19365094
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Maurillo L; Breccia M; Buccisano F; Voso MT; Niscola P; Trapè G; Tatarelli C; D'Addosio A; Latagliata R; Fenu S; Piccioni AL; Fragasso A; Aloe Spiriti MA; Refrigeri M; Criscuolo M; Musto P; Venditti A
Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
Chen CH; Shu KH; Yang Y
Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of deferasirox in myelodysplastic syndromes.
Breccia M; Alimena G
Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
[TBL] [Abstract][Full Text] [Related]
18. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
Tsouana E; Kaya B; Gadong N; Hemmaway C; Newell H; Simmons A; Whitmarsh S; Telfer P
Eur J Haematol; 2015 Apr; 94(4):336-42. PubMed ID: 25138173
[TBL] [Abstract][Full Text] [Related]
19. Delineating parameters of iron overload in MDS patients treated with deferasirox.
Leitch HA
Leuk Res; 2010 Dec; 34(12):1556-7. PubMed ID: 20719382
[No Abstract] [Full Text] [Related]
20. Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
Raphael JL; Bernhardt MB; Mahoney DH; Mueller BU
Pediatr Blood Cancer; 2009 May; 52(5):616-20. PubMed ID: 19148949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
